The Nasdaq jumped by around 190 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform.
Costco Wholesale
- The Trade: Costco Wholesale Corporation COST Executive Vice President James Klauer sold a total of 2,500 shares at an average price of $503.69. The insider received around $1.26 million from selling those shares.
- What’s Happening: Costco reauthorized a buyback and declared a dividend.
- What Costco Wholesale Does: The leading warehouse club, Costco has 838 stores worldwide (at the end of fiscal 2022), with most sales derived in the United States (73%) and Canada (14%).
Check This Out: Electronic Arts, Western Digital And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Micron Technology
- The Trade: Micron Technology, Inc. MU EVP, Global Operations Manish Bhatia sold a total of 50,000 shares at an average price of $63.29. The insider received around $3.16 million as a result of the transaction.
- What’s Happening: Micron, during December, reported worse-than-expected Q1 results.
- What Micron Technology Does: Micron historically focused on designing and manufacturing DRAM for PCs.
Have a look at our premarket coverage here
DexCom
- The Trade: DexCom, Inc. DXCM President, CEO and Chairman Kevin R Sayer sold a total of 56,844 shares at an average price of $106.15. The insider received around $6.03 million from selling those shares.
- What’s Happening: DexCom recently reported preliminary Q4 and FY22 revenue results.
- What DexCom Does: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.